Down-regulation synaptic vesicle protein 2A in the anterior temporal neocortex of patients with intractable Epilepsy

Journal of Molecular Neuroscience

Volumn 39, Issue 3, 2009, Pages 354-359

  Feng, Guibo ^a   Xiao, Fei ^a   Lu, Yang ^a   Huang, Zuchun ^a   Yuan, Jie ^a   Xiao, Zheng ^a   Xi, Zhiqin ^a   Wang, Xuefeng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Epilepsy; Synaptic vesicle protein 2A (SV2A); Temporal lobe

Indexed keywords

CELL PROTEIN; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRACTABLE EPILEPSY; MALE; NEOCORTEX; NERVE CELL; NEUROSURGERY; RECEPTOR DOWN REGULATION; STAINING; TEMPORAL LOBE; WESTERN BLOTTING;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DOWN-REGULATION; EPILEPSY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOCORTEX; NERVE TISSUE PROTEINS; NEURONS; TEMPORAL LOBE; YOUNG ADULT;

ANIMALIA;

EID: 73849149840     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-009-9288-2     Document Type: Article

References (19)

1. Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH (1994) Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci 14:5223-5235
2. Bennett B, Matagne A, Michel P et al (2007) Seletracetam (UCB 44212). Neurotherapeutics 4:117-122
3. Buckley K, Kelly RB (1985) Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol 100:1284-1294
4. Chang WP, Sudhof TC (2009) SV2 renders primed synaptic vesicles competent for Ca2+ -induced exocytosis. J Neurosci 29(4):883-897
5. Crowder KM, Gunther JM, Jones TA et al (1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci 96:15268-15273
6. Gillard M, Chatelain P, Fuks B (2006) Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 536:102-108
7. Janz R, Sudhof TC (1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94:1279-1290
8. 2+ regulators in neurotransmitter release. Neuron 24:1003-1016
9. Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314-319
10. Lynch BA, Lambeng N, Nocka K et al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci 101:9861-9866
11. Regesta G, Tanganelli P (1999) Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 34:109-122
12. Rogawski MA, Loscher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553-564
13. Scheuer ML, Pedley TA (1990) The evaluation and treatment of seizures. N Engl J Med 323:1468-1474
14. Schmidt D, Loscher W (2005) Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46:858-877 (Pubitemid 40847354)
15. Sisodiya SM (2003) Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 16:197-201
16. Toering ST, Boer K, de Groot M et al (2009) Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSCcortical tubers. Epilepsia 50(6):1409-1418
17. van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA (2009) Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 50(3):422-33
18. von Rosenstiel P (2007) Brivaracetam (UCB 34714). Neurotherapeutics 4:84-87
19. Xiao Z, Gong Y, Wang X-F et al (2009) Altered expression of synaptotagmin I in temporal lobe tissue of patients with refractory epilepsy. J Mol Neurosci 38(2):193-200